Overview

Durvalumab in Pediatric and Adolescent Patients

Status:
Unknown status

Trial end date:
2020-12-01

Target enrollment:

Participant gender:

Summary

This clinical trial is the first clinical trial to study Durvalumab, a checkpoint inhibitor which stimulates the patient's own immune system to act against cancer cells in children and adolescents. This trial will assess the safety and tolerability of Durvalumab in children and adolescents and also study how Durvalumab is processed in their bodies.

Phase:

Phase 1

Details

Lead Sponsor:

Children's Hospital Los Angeles

Treatments:

Antibodies, Monoclonal
Durvalumab